Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Contingent consideration liabilities by Quarter
Contingent consideration liabilities — Current (historical, $M) ($M)
Vertex Pharmaceuticals Contingent consideration liabilities: $0M in Q4 2023, down 100.0% from a year earlier. No newer figure appears in the documents we track.
Where the Q4 2023 figure comes from
Source: Form 10-K (filed 2024-02-15) ↗
Reported in Form 10-K Fair Value Measurements Note.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Contingent consideration liabilities — Current (historical, $M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2023 | Dec 31, 2023 | 0 | -100.0% | Form 10-K (filed 2024-02-15) ↗ |
| Q3 2023 | Sep 30, 2023 | 15 | – | Form 10-Q (filed 2023-11-07) ↗ |
| Q2 2023 | Jun 30, 2023 | 15 | – | Form 10-Q (filed 2023-08-02) ↗ |
| Q1 2023 | Mar 31, 2023 | 14.8 | – | Form 10-Q (filed 2023-05-02) ↗ |
| Q4 2022 | Dec 31, 2022 | 14.6 | – | Form 10-K (filed 2024-02-15) ↗ |
| Q4 2021 | Dec 31, 2021 | 0 | – | Form 10-K (filed 2023-02-10) ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals Contingent consideration liabilities ($M), quarterly Q4 2021–Q4 2023 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/cc-liab-cur
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.